Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727880 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Lei Zheng.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03727880 is a Phase 2 study that has completed, run by Lei Zheng. The registered enrollment target is 28 participants.
The verdict
NCT03727880, a Phase 2 study, has completed, sponsored by Lei Zheng.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.
Interventions
- DRUG Pembrolizumab
- DRUG Defactinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03727880
The ClinicalTrials.gov registry entry for NCT03727880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lei Zheng, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03727880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03727880 about?
NCT03727880 is a clinical study titled "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma". This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kin...
What is the current status of trial NCT03727880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-06-04. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT03727880?
The interventions under investigation include: Pembrolizumab (DRUG), Defactinib (DRUG).
Who is sponsoring clinical trial NCT03727880?
This trial is sponsored by Lei Zheng, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.